3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Advanced or Metastatic Solid Tumors
3
Solid Tumors
2
Sarcoma
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms
2
Solid Tumor
1
Histiocytoma, Malignant Fibrous
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
2
Ipilimumab
2
Doxorubicin
2
soblidotin
1
reolysin
1
olaratumab
1
futibatinib
1
envafolimab
1
brigimadlin
1
belinostat
1
Injections
1
Immune Checkpoint Inhibitors
1
Ifosfamide
1
Histamine H2 Antagonists
1
Gemcitabine
1
Fluorouracil
1
Famotidine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Histiocytoma, Malignant Fibrous
×
envafolimab
×
Clear all
NCT04480502
2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2
Unknown
207 enrolled